Instability of sputum molecular phenotypes in U-BIOPRED severe asthma

Nazanin Z. Kermani; Stelios Pavlidis; Jiaxing Xie; Kai Sun; Matthew Loza; Fred Baribaud; Steve J. Fowler; Dominic E. Shaw; Louise J. Fleming; Peter H. Howarth; Ana R. Sousa; Julie Corfield; Charles Auffray; Bertrand de Meulder; Peter J. Sterk; Yike Guo; Mohib Uddin; Ratko Djukanovic; Ian M. Adcock; Kian Fan Chung

doi:https://doi.org/10.1183/13993003.01836-2020

Instability of sputum molecular phenotypes in U-BIOPRED severe asthma

Nazanin Z. Kermani, Stelios Pavlidis, Jiaxing Xie, Kai Sun, Matthew Loza, Fred Baribaud, Steve J. Fowler, Dominic E. Shaw, Louise J. Fleming, Peter H. Howarth, Ana R. Sousa, Julie Corfield, Charles Auffray, Bertrand de Meulder, Peter J. Sterk, Yike Guo, Mohib Uddin, Ratko Djukanovic, Ian M. Adcock, Kian Fan Chung

Pulmonology (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

Original language	English
Article number	2001836
Journal	European Respiratory Journal
Volume	57
Issue number	2
DOIs	https://doi.org/10.1183/13993003.01836-2020 https://doi.org/10.1183/13993003.01836-2020
Publication status	Published - 1 Feb 2021

Access to Document

Cite this

Kermani, N. Z., Pavlidis, S., Xie, J., Sun, K., Loza, M., Baribaud, F., Fowler, S. J., Shaw, D. E., Fleming, L. J., Howarth, P. H., Sousa, A. R., Corfield, J., Auffray, C., de Meulder, B., Sterk, P. J., Guo, Y., Uddin, M., Djukanovic, R., Adcock, I. M., & Chung, K. F. (2021). Instability of sputum molecular phenotypes in U-BIOPRED severe asthma. European Respiratory Journal, 57(2), Article 2001836. https://doi.org/10.1183/13993003.01836-2020, https://doi.org/10.1183/13993003.01836-2020

@article{886ccaa904b444439fc39cba44f6b4f0,

title = "Instability of sputum molecular phenotypes in U-BIOPRED severe asthma",

author = "Kermani, {Nazanin Z.} and Stelios Pavlidis and Jiaxing Xie and Kai Sun and Matthew Loza and Fred Baribaud and Fowler, {Steve J.} and Shaw, {Dominic E.} and Fleming, {Louise J.} and Howarth, {Peter H.} and Sousa, {Ana R.} and Julie Corfield and Charles Auffray and {de Meulder}, Bertrand and Sterk, {Peter J.} and Yike Guo and Mohib Uddin and Ratko Djukanovic and Adcock, {Ian M.} and Chung, {Kian Fan}",

note = "Funding Information: Conflict of interest: N.Z. Kermani has nothing to disclose. S. Pavlidis has nothing to disclose. J. Xie has nothing to disclose. K. Sun has nothing to disclose. M. Loza is an employee and shareholder of Janssen R&D, Pharmaceutical Companies of Johnson & Johnson. F. Baribaud is an employee and shareholder of Janssen R&D, Pharmaceutical Companies of Johnson & Johnson. S.J. Fowler reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study; personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Novartis, outside the submitted work. D.E. Shaw reports personal fees from GSK, AstraZeneca, Teva and Boehringer Ingelheim, outside the submitted work. L.J. Fleming reports personal fees for advisory board membership from Novartis, Vectura and Boehringer Ingelheim; grants for research from Asthma UK and BLF; personal fees for lectures from Novartis, outside the submitted work. P.H. Howarth reports part time employment by GSK as Global Medical Expert. A.R. Sousa has nothing to disclose. J. Corfield has nothing to disclose. C. Auffray has nothing to disclose. B. De Muelder has nothing to disclose. P.J. Sterk reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study. Y. Guo has nothing to disclose. M. Uddin is an employee of AstraZeneca and holds shares in the company. R. Djukanovic reports personal fees from TEVA, grants and personal fees from Novartis, and personal fees and other support from Synairgen outside the submitted work. I.M. Adcock reports personal fees for advisory board membership from GSK, AstraZeneca, Novartis, Boehringer Ingelehim and Vectura; grants from Pfizer, GSK, MRC, EU, Boehringer Ingelheim and Innovative Medicines Initiative (IMI); and personal fees for lectures, outside the submitted work. K.F. Chung has received honoraria for participating on advisory board meetings of GSK, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Roche and TEVA regarding treatments for asthma and COPD and on the scientific advisory board of the Clean Breathing Institute supported by GSK Health Care Consumer Products; and has also been remunerated for speaking engagements by AstraZeneca, Novartis and Merck, outside the submitted work. Funding Information: Support statement: The U-BIOPRED project is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement 115010, resources of which are composed of financial contributions from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations companies{\textquoteright} in-kind contributions (www.imi.europa.eu). Funding information for this article has been deposited with the Crossref Funder Registry. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = feb,

day = "1",

doi = "https://doi.org/10.1183/13993003.01836-2020",

language = "English",

volume = "57",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

Kermani, NZ, Pavlidis, S, Xie, J, Sun, K, Loza, M, Baribaud, F, Fowler, SJ, Shaw, DE, Fleming, LJ, Howarth, PH, Sousa, AR, Corfield, J, Auffray, C, de Meulder, B, Sterk, PJ, Guo, Y, Uddin, M, Djukanovic, R, Adcock, IM & Chung, KF 2021, 'Instability of sputum molecular phenotypes in U-BIOPRED severe asthma', European Respiratory Journal, vol. 57, no. 2, 2001836. https://doi.org/10.1183/13993003.01836-2020, https://doi.org/10.1183/13993003.01836-2020

TY - JOUR

T1 - Instability of sputum molecular phenotypes in U-BIOPRED severe asthma

AU - Kermani, Nazanin Z.

AU - Pavlidis, Stelios

AU - Xie, Jiaxing

AU - Sun, Kai

AU - Loza, Matthew

AU - Baribaud, Fred

AU - Fowler, Steve J.

AU - Shaw, Dominic E.

AU - Fleming, Louise J.

AU - Howarth, Peter H.

AU - Sousa, Ana R.

AU - Corfield, Julie

AU - Auffray, Charles

AU - de Meulder, Bertrand

AU - Sterk, Peter J.

AU - Guo, Yike

AU - Uddin, Mohib

AU - Djukanovic, Ratko

AU - Adcock, Ian M.

AU - Chung, Kian Fan

N1 - Funding Information: Conflict of interest: N.Z. Kermani has nothing to disclose. S. Pavlidis has nothing to disclose. J. Xie has nothing to disclose. K. Sun has nothing to disclose. M. Loza is an employee and shareholder of Janssen R&D, Pharmaceutical Companies of Johnson & Johnson. F. Baribaud is an employee and shareholder of Janssen R&D, Pharmaceutical Companies of Johnson & Johnson. S.J. Fowler reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study; personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Novartis, outside the submitted work. D.E. Shaw reports personal fees from GSK, AstraZeneca, Teva and Boehringer Ingelheim, outside the submitted work. L.J. Fleming reports personal fees for advisory board membership from Novartis, Vectura and Boehringer Ingelheim; grants for research from Asthma UK and BLF; personal fees for lectures from Novartis, outside the submitted work. P.H. Howarth reports part time employment by GSK as Global Medical Expert. A.R. Sousa has nothing to disclose. J. Corfield has nothing to disclose. C. Auffray has nothing to disclose. B. De Muelder has nothing to disclose. P.J. Sterk reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study. Y. Guo has nothing to disclose. M. Uddin is an employee of AstraZeneca and holds shares in the company. R. Djukanovic reports personal fees from TEVA, grants and personal fees from Novartis, and personal fees and other support from Synairgen outside the submitted work. I.M. Adcock reports personal fees for advisory board membership from GSK, AstraZeneca, Novartis, Boehringer Ingelehim and Vectura; grants from Pfizer, GSK, MRC, EU, Boehringer Ingelheim and Innovative Medicines Initiative (IMI); and personal fees for lectures, outside the submitted work. K.F. Chung has received honoraria for participating on advisory board meetings of GSK, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Roche and TEVA regarding treatments for asthma and COPD and on the scientific advisory board of the Clean Breathing Institute supported by GSK Health Care Consumer Products; and has also been remunerated for speaking engagements by AstraZeneca, Novartis and Merck, outside the submitted work. Funding Information: Support statement: The U-BIOPRED project is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement 115010, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions (www.imi.europa.eu). Funding information for this article has been deposited with the Crossref Funder Registry. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/2/1

Y1 - 2021/2/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85101241274&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/33008937

U2 - https://doi.org/10.1183/13993003.01836-2020

DO - https://doi.org/10.1183/13993003.01836-2020

M3 - Article

C2 - 33008937

SN - 0903-1936

VL - 57

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

M1 - 2001836

ER -

Instability of sputum molecular phenotypes in U-BIOPRED severe asthma

Access to Document

Other files and links

Cite this